National Survey on Hypertension (SERENITE)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00804167
First received: December 5, 2008
Last updated: July 19, 2009
Last verified: July 2009
  Purpose

Describe the clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage


Condition
Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Profile of Hypertensive Patients Aged of 75 Years and Older Seen in General Practitioner According to Their Renal Damage.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Describe the clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage [ Time Frame: once ] [ Designated as safety issue: No ]

Estimated Enrollment: 4500
Study Start Date: December 2008
Study Completion Date: July 2009
  Eligibility

Ages Eligible for Study:   75 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The first 3 consecutive patients seen during the GP's visit with a diagnosis of Hypertension and with renal damage

Criteria

Inclusion Criteria:

  • Male or female aged 75 years or older
  • With a diagnosis of Hypertension treated or not, seen in general practitioner consultation
  • Who has given his/her consent to participate to the study.

Exclusion Criteria:

  • Patient who participated to a clinical trial
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00804167

  Show 1300 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne, Medical Director AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00804167     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2008/1
Study First Received: December 5, 2008
Last Updated: July 19, 2009
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Hypertensive patients aged of 75 years and older
renal damage
Clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 15, 2014